Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/120386
Title: | Hepatocellular carcinoma |
Author: | Llovet i Bayer, Josep Maria Zucman-Rossi, Jessica Pikarsky, Eli Sangro, Bruno Schwartz, Myron Sherman, Morris Gores, Gregory |
Keywords: | Càncer de fetge Oncologia Cirrosi hepàtica Hepatitis vírica Liver cancer Oncology Hepatic cirrhosis Viral hepatitis |
Issue Date: | 14-Apr-2016 |
Abstract: | Liver cancer is the second leading cause of cancer-related deaths globally and has an incidence of approximately 850,000 new cases per year. Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer. The main risk factors for developing HCC are well known and include hepatitis B and C virus infection, alcohol intake and ingestion of the fungal metabolite aflatoxin B1. Additional risk factors such as non-alcoholic steatohepatitis are also emerging. Advances in the understanding of the molecular pathogenesis of HCC have led to identification of critical driver mutations; however, the most prevalent of these are not yet druggable targets. The molecular classification of HCC is not established, and the Barcelona Clinic Liver Cancer staging classification is the main clinical algorithm for the stratification of patients according to prognosis and treatment allocation. Surveillance programmes enable the detection of early-stage tumours that are amenable to curative therapies - resection, liver transplantation or local ablation. At more developed stages, only chemoembolization (for intermediate HCC) and sorafenib (for advanced HCC) have shown survival benefits. There are major unmet needs in HCC management that might be addressed through the discovery of new therapies and their combinations for use in the adjuvant setting and for intermediate- and advanced-stage disease. Moreover, biomarkers for therapy stratification, patient-tailored strategies targeting driver mutations and/or activating signalling cascades, and validated measurements of quality of life are needed. Recent failures in the testing of systemic drugs for intermediate and advanced stages have indicated a need to refine trial designs and to define novel approaches. |
Note: | https://doi.org/10.1038/nrdp.2016.18 |
It is part of: | Nature Reviews Disease Primers, 2016, vol.2; num. 16018 |
URI: | http://hdl.handle.net/2445/120386 |
Related resource: | https://doi.org/10.1038/nrdp.2016.18 |
ISSN: | 2056-676X |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Publicacions de projectes de recerca finançats per la UE |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
657131.pdf | 644.26 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.